Share This! Tweet This! Recommend Us! Print Page
Language

Neurology

Find a Doctor
Find a Location

Neurology - Research

The MultiCare Neuroscience Center of Washington has been active in the search for new and innovative treatments for many of the devastating neurologic diseases that affect our community. The MultiCare Research Institute has partnered with the MultiCare Neuroscience Center of Washington to provide research opportunities to our community in many areas of neurologic science including:

Multiple Sclerosis

John Huddlestone, MD and the site are nationally recognized for excellence. He has been involved in clinical trials for more then 2 decades. Trials are conducted at South Sound’s only nationally recognized Multiple Sclerosis Center. The site has participated in trials evaluating

  • First oral medications for treatment of MS
  • Monoclonal antibody therapy in MS
  • Novel therapeutics with specific targets in MS
  • Comparison of Disease Modifying Therapies in MS
  • Long-term follow-up trials after Exposure to Investigational Products

Post-Herpetic Neuralgia pain control

Restless Leg Syndrome control of symptoms

Migraine Headache treatment and suppression

Movement Disorders treatment

Epilepsy

Two Board Certified Epileptologists, Laura Hershkowitz, DO and Laura Lynam, MD offer clinical trials to patients with epilepsy.


The Investigators in Neuroscience medicine include:

Laura Hershkowitz, DO, FACN (Principal Investigator)

John Huddlestone, MD, FAAN (Principal Investigator)

Peter Kwon, MD

Laura Lynam, MD,

Traci Ryan, MD

Yu Zhu, MD, PhD

Neurology Studies Accepting Participants

Multiple Sclerosis - Relapse (Ages 18-55)
 

Study Number: 14-NEU-07
Title: Trevo® Retriever Registry
Websitehttps://clinicaltrials.gov/
Purpose: The purpose of the Trevo Registry is to collect information (data) on a medical device called the Trevo Retriever

Who Can Participate? Patients whose doctors have used, or will be using the Trevo Retriever device to treat stroke
Diagnosis or Condition: Acute Stroke
Device: Trevo Retriever

Age:  Any Age

Sex: Males and Females

Visits:   Patients will have 2 visits following their procedure, one via telephone at 30 days and then a clinic visit and 90 days

Stipend: You will be compensated for your time and travel
 
Principal Investigator(s)Brian Kott, MD

Study Coordinator:   Janey Barnhart, RN, CNRN, Research Nurse 253-403-7258


 

Study Number: 14-NEU-08
Title: A phase 4 multicenter, open label, single arm study to evaluate switching from BRACET/Gilenya to Natulizumab in subjects with relapsing forms of Multiple Sclerosis (MS)
Websitehttps://clinicaltrials.gov/
Purpose:  
The main purpose of this study is to determine the efficacy of Tysabri (natalizumab) as compared to the previous therapy.  This study is seeking patients with relapsing forms of MS who have had documented evidence of clinical MRI disease activity during the last six months while on an oral or injectable FDA approved therapy and are eligible for Tysabri therapy under FDA labeling regulations.

Who Can Participate? All patients who meet the above criteria
Diagnosis or Condition: Multiple Sclerosis
Medication: Tysabri

Age: 18-60 

Sex: Males and Females

Visits: Patients will be seen 13 times (not including infusions) over the course of a little more than two years

Stipend: You may be compensated for your time and travel

Principal Investigator(s):  John Huddlestone, MD, FAAN

Study Coordinator: Jarrod Monroe, BS, CRC 253-403-7449 and Courtney Lumsden, BS, CRC 253-403-7440
 

Neuropathic Pain
Study Number: 14-NEU-05
Title: A Phase 2/3, Multi-Center, Randomized, Double-blind, Placebo-Controlled (Part A) and Double-Blind, Double-Dummy, Active Controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients (Part B only)
Websitehttps://clinicaltrials.gov/
Purpose: The purpose of this research study is to determine if an experimental drug is safe and effective in the possible treatment of MS compared with standard treatment. This study is seeking patients with MS who have either had a relapse in the last 12 months, OR has had 1 documented relapse in the last 24 months AND has evidence of specific lesions on an MRI scan in the last 12 months

Who Can Participate? All patients who meet the above criteria, along with other assessments the study coordinator can tell you about
Diagnosis or Condition: Multiple Sclerosis
Medication: An Investigational Medication

Age: Between 18 and 55

Sex: Males and Females

Visits:  Patients will be followed for 2 years with up to 12 scheduled visits

Stipend: You may be compensated for your time and travel

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator: Jarrod Monroe, BS, CRC 253-403-7449 and Courtney Lumsden, BS, CRC 253-403-7440



Study Number: 13-NEU-07
Title: A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (dimethyl fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate
Websitehttps://clinicaltrials.gov/
Purpose:  
The purpose of the study is to find out more about the effectiveness of Tecfidera on relapse rate and quality of life in patients with MS who were previously treated with glatiramer acetate (Copaxone®)

Who Can Participate? Patients who have taken Copaxone as disease modifying therapy, whose doctor has decided to change their therapy to Tecfidera, and who meet all other study criteria. This study is seeking patients who are starting Tecfidera for the first time
Diagnosis or Condition: Multiple Sclerosis
Medication: This is an observational study only with no investigational medication. Patients will take commercially available Tecfidera as prescribed by their doctor

Age: 18 or older

Sex: Males and Females

Visits: Paients will be seen at their regularly scheduled visits with their MS provider and will not have extra procedures. Patients will have the option to complete questionnaires

Stipend: You may be compensated for your time and travel

Principal Investigator(s):  John Huddlestone, MD, FAAN

Study Coordinator: Jarrod Monroe, BS, CRC 253-403-7449 and Courtney Lumsden, BS, CRC 253-403-7440



Study Number: 14-NEU-01
Title: A Placebo-Controlled Randomized Withdrawal Evaluation of the Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects with Spasticity Due to Multiple Sclerosis
Websitehttps://clinicaltrials.gov/
Purpose: The purpose of this research study is to gather scientific information about the long-term safety and efficacy of the investigational new drug, SPARC’s Baclofen ER Capsules (Gastro-Retentive System [GRS]) in subjects with spasticity due to MS

Who can participate? Patients with spasticity due to MS who meet the above criteria, have acceptable symptom control while on immediate release Baclofen, and who meet the study criteria
Diagnosis or condition: Multiple Sclerosis (MS)
Medication: Baclofen Extended Release Capsules

Age: 18 and older

Sex: Males and Females

Visits: Patients will have 12 visits over approximately 5 months

Stipend: Patients may be compensated for their time and travel

Principal Investigator(s):  John Huddlestone, MD, FAAN

Study Coordinator: Jarrod Monroe, BS, CRC 253-403-7449 and Courtney Lumsden, BS, CRC 253-403-7440



Study Number: 13-NEU-09
Title: A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)
Websitehttps://clinicaltrials.gov/
Purpose: This study is being done to gain a better understanding of the benefits and risks of long-term treatment with Tecfidera™ in patients with multiple sclerosis (MS).  The main purpose of this observational study is to collect information on any serious side effects that may occur in patients taking Tecfidera™

Who can participate? Patients with MS who have been newly prescribed DMF under routine clinical care are eligible to participate in the study
Diagnosis: Multiple Sclerosis
Medication: No investigational medication

Age: 12 and older

Sex: Males and Female

Visits: Data will be collected at routine visits only. No additional study visits required

Principal Investigator(s):  John Huddlestone, MD, FAAN

Study Coordinator: Jarrod Monroe, BS, CRC 253-403-7449 and Courtney Lumsden, BS, CRC 253-403-7440